IL128781A0 - Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride - Google Patents
Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochlorideInfo
- Publication number
- IL128781A0 IL128781A0 IL12878197A IL12878197A IL128781A0 IL 128781 A0 IL128781 A0 IL 128781A0 IL 12878197 A IL12878197 A IL 12878197A IL 12878197 A IL12878197 A IL 12878197A IL 128781 A0 IL128781 A0 IL 128781A0
- Authority
- IL
- Israel
- Prior art keywords
- alpha
- methoxyimino
- azabicyclo
- oct
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL128781A0 true IL128781A0 (en) | 2000-01-31 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12878197A IL128781A0 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (id) |
| JP (1) | JP2001500150A (id) |
| KR (1) | KR20000036039A (id) |
| CN (2) | CN1235544A (id) |
| AR (1) | AR008176A1 (id) |
| AU (1) | AU724086B2 (id) |
| BR (1) | BR9711734A (id) |
| CA (1) | CA2265661A1 (id) |
| CO (1) | CO5031291A1 (id) |
| CZ (1) | CZ83299A3 (id) |
| GB (1) | GB9619074D0 (id) |
| HU (1) | HUP9904401A3 (id) |
| ID (1) | ID19589A (id) |
| IL (1) | IL128781A0 (id) |
| MA (1) | MA24359A1 (id) |
| NO (1) | NO991194L (id) |
| NZ (1) | NZ334268A (id) |
| PE (1) | PE2499A1 (id) |
| PL (1) | PL332074A1 (id) |
| TR (1) | TR199900505T2 (id) |
| WO (1) | WO1998010762A2 (id) |
| ZA (1) | ZA978133B (id) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| AU748396C (en) * | 1998-03-11 | 2003-01-23 | Smithkline Beecham Corporation | Composition |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| JP4808612B2 (ja) * | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
| EP1628642B2 (en) * | 2003-05-14 | 2013-01-23 | Aptalis Pharma Limited | Controlled drug release composition resistant to in vivo mechanic stress |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| CA2576386A1 (en) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| PL1789021T3 (pl) | 2004-08-13 | 2012-04-30 | Boehringer Ingelheim Int | Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0392803B1 (en) * | 1989-04-13 | 2004-06-16 | Beecham Group p.l.c. | Novel compounds |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
-
1999
- 1999-03-11 NO NO991194A patent/NO991194L/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR9711734A (pt) | 1999-08-24 |
| ID19589A (id) | 1998-07-23 |
| CO5031291A1 (es) | 2001-04-27 |
| EP0929301A2 (en) | 1999-07-21 |
| HUP9904401A2 (hu) | 2000-06-28 |
| CN1235544A (zh) | 1999-11-17 |
| TR199900505T2 (id) | 1999-06-21 |
| PL332074A1 (en) | 1999-08-30 |
| CN1446535A (zh) | 2003-10-08 |
| NO991194D0 (no) | 1999-03-11 |
| AR008176A1 (es) | 1999-12-09 |
| CZ83299A3 (cs) | 1999-08-11 |
| HUP9904401A3 (en) | 2001-03-28 |
| KR20000036039A (ko) | 2000-06-26 |
| NO991194L (no) | 1999-03-11 |
| WO1998010762A3 (en) | 1998-06-04 |
| MA24359A1 (fr) | 1998-07-01 |
| CA2265661A1 (en) | 1998-03-19 |
| AU724086B2 (en) | 2000-09-14 |
| NZ334268A (en) | 2000-10-27 |
| ZA978133B (en) | 1999-04-12 |
| GB9619074D0 (en) | 1996-10-23 |
| WO1998010762A2 (en) | 1998-03-19 |
| JP2001500150A (ja) | 2001-01-09 |
| AU4128897A (en) | 1998-04-02 |
| PE2499A1 (es) | 1999-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL128781A0 (en) | Controlled release dosage form of (R-(Z))-alpha-(methoxyimino)-alpha-(1-azabicyclo(2.2.2)oct-3-yl) acetonitrile monohydrochloride | |
| HUP0101043A3 (en) | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation | |
| EP1017980A4 (en) | METHOD FOR IDENTIFYING PHARMACEUTICALLY ACTIVE COMPOUNDS | |
| HUP0003737A3 (en) | New process for the preparation of omeprazole | |
| GB9815383D0 (en) | Novel method of treatment | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| GB9821967D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| GB9821966D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim | |
| ZA981679B (en) | Pharmaceutical composition for the programmed release of dexfenfluramine | |
| IL114522A (en) | Process for the preparation of alpha-(oximino)-alpha-(1-azabicyclo¬2.2.2¾oct-3-yl) acetonitrile derivatives | |
| GB9602667D0 (en) | Pharmaceutically active compounds | |
| GB9618487D0 (en) | Pharmaceutically active compounds | |
| GB9602173D0 (en) | Pharmaceutically active compounds | |
| GB9602668D0 (en) | Pharmaceutically active compounds | |
| GB9610474D0 (en) | Pharmaceutically active compounds | |
| GB9610499D0 (en) | Pharmaceutically active compounds | |
| GB9610892D0 (en) | Pharmaceutically active compounds | |
| GB9614385D0 (en) | Pharmaceutically active compounds | |
| GB9619122D0 (en) | Pharmaceutically active compounds | |
| GB9614386D0 (en) | Pharmaceutically active compounds | |
| GB9616477D0 (en) | Pharmaceutically active compounds | |
| GB9319835D0 (en) | Pharmaceutically active compounds | |
| GB9305997D0 (en) | Pharmaceutically active compounds | |
| GB9323345D0 (en) | Pharmaceutically active compounds | |
| GB9325410D0 (en) | Pharmaceutically active compounds |